Standardisation of the quantitation of serum amyloid A protein (SAA) in human serum.
An adequate method for standardising the quantitation of serum amyloid A protein (SAA) in human serum was developed. Acute phase high density lipoprotein3 (HDL3) was used as a standard. The concentration of the SAA in the standard was determined by the use of purified SAA. After protein determination, various concentrations of purified SAA were run on SDS-polyacrylamide gel together with the HDL3 standard containing an unknown amount of SAA amongst the apolipoproteins. From the standard curve obtained by pyridine extraction (Coomassie blue colour yield at A605 nm) the concentration of SAA in the HDL3 standard was determined. An established immunoradiometric assay (IRMA) for SAA was standardised with the HDL3. SAA concentrations in normal and acute phase sera were determined.
D000682:Amyloid / Q000032:analysis*; D002914:Chylomicrons / Q000032:analysis; D006801:Humans; D008075:Lipoproteins, HDL / Q000032:analysis*; D008077:Lipoproteins, LDL / Q000032:analysis; D008079:Lipoproteins, VLDL / Q000032:analysis; D009203:Myocardial Infarction / Q000097:blood; D011014:Pneumonia / Q000097:blood; D011863:Radioimmunoassay; D000685:Serum Amyloid A Protein / Q000032:analysis*
D000682:Amyloid; D002914:Chylomicrons; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D008079:Lipoproteins, VLDL; D000685:Serum Amyloid A Protein